Acumen Pharmaceuticals Inc (ABOS) Straddle

Trading a ABOS straddle lets you take a pure volatility position on Acumen Pharmaceuticals Inc without committing to a direction. Acumen Pharmaceuticals Inc's straddle involves buying (or selling) a call and a put at the same strike and expiration, profiting when the stock moves more (or less) than the combined premium implies. Use our scanner to evaluate ABOS straddle pricing in real time and find the moments when expected moves are mispriced.

A long straddle on ABOS profits from large moves in either direction and is a classic play into binary events like earnings, product announcements, or macro releases. A short straddle profits when Acumen Pharmaceuticals Inc stays range-bound and implied volatility contracts. The breakeven points are simple: strike plus total premium on the upside, strike minus total premium on the downside. Comparing the ABOS straddle price to historical realized moves helps you judge whether the market is overpaying or underpaying for volatility.

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

Earnings, product cycles, macro prints — any time volatility itself is the trade, the ABOS straddle is the cleanest expression of that view. Our scanner prices every ABOS straddle against historical realized moves, flags expirations where the market is overpaying or underpaying for vol, and ranks setups by breakeven width and IV rank. Whether you're long a ABOS straddle into a catalyst or short a ABOS straddle to harvest decay, the options straddle setups that matter are all in one place.